Our actions
and publications.

Discover the club’s work, collective initiatives and scientific contributions.

Our actions Our publications

01 / SCIENTIFIC LIFE

Our actions

01
Centre mapping
Mapping of centres offering CAR-T cells and T-cell engagers in clinical studies, in collaboration with FAI2R.
02
Patient information
Emergency card and patient information document for people treated with CAR-T cells.
03
Training and webinars
Training sessions and webinars on innovative therapies in IMIDs.

02 / SCIENTIFIC CONTRIBUTIONS

Our publications

Published online on October 7, 2026
Next-generation immune cell engagers for B cell depletion in autoimmune diseases
Fu Y, Robert B, Bitoun S, Martineau P, Konig MF, Avouac J, Tsokos GC, Ye S, Scherlinger M.
Nature Reviews Drug Discovery. 2026. Publication en ligne avant attribution à un numéro.
DOI: 10.1038/s41573-026-01534-z
Published online on September 7, 2026
Suspected ICANS in systemic sclerosis: think twice before corticosteroids
Boyer M, Sebbag E, Collongues N, Florens N, Storck W, El-Aatmani A, Walther J, Castelain V, Mariaseelan S, Grass L, Sibilia J, Gottenberg JE, Scherlinger M.
Rheumatology. 2026;65(9):keag485.
DOI: 10.1093/rheumatology/keag485 PubMed
Published online on September 3, 2026
Immune reset after deep B-lineage depletion: remission is not reprogramming Open access
Scherlinger M, Avouac J, Tsokos GC.
Annals of the Rheumatic Diseases. 2026 Sep 3:S0003-4967(26)00473-5. Publication en ligne avant attribution à un numéro.
DOI: 10.1016/j.ard.2026.07.016 PubMed
Published online on August 14, 2026
The why, what, who and when of B cell depletion in systemic lupus erythematosus: biological rationale, patient stratification and evolving therapeutic modalities Open access
Wincup C, Gatto M, Scherlinger M, Schett G, Hagen M.
Rheumatology. 2026;65(8):keag416.
DOI: 10.1093/rheumatology/keag416 PubMed
Published online on March 6, 2026
Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series Open access
Scherlinger M, Dieudonné Y, Hilliquin S, Chatelus E, d'Alessandro R, Gies V, Nespola B, Martin T, Gottenberg JE, Simand C, El Aatmani A, Brandely-Piat ML, Sebbag E, Decroocq J, Sibilia J, Allanore Y, Avouac J.
Annals of the Rheumatic Diseases. 2026;85(6):1172–1179.
DOI: 10.1016/j.ard.2026.02.002 PubMed
Published online on January 26, 2026
Roads and detours for CAR T cell therapy in autoimmune diseases
Avouac J, Barzel A, Caiati D, Davis RS, Gottschalk S, Grieshaber-Bouyer R, Mao X, Luning Prak ET, Radic M, Scherlinger M, Suneja Y, Talleur A, Thacker AL, Unutmaz D.
Nature Reviews Drug Discovery. 2026;25(4):290–309.
DOI: 10.1038/s41573-025-01349-4 PubMed
Published online on May 10, 2025
CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future? Open access
Jouret M, Viel S, Fournier B, Benezech S, Avouac J, Scherlinger M, Belot A; C3I consortium.
Arthritis Research & Therapy. 2025;27(1):102.
DOI: 10.1186/s13075-025-03564-1 PubMed
Published online on March 26, 2025
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
Scherlinger M, Nocturne G, Radic M, Launay D, Richez C, Bousso P, Forcade E, Meyer A, Jorgensen C, Bigenwald C, Cornec D, Sibilia J, Choquet S, Martin T, Belot A, Jouret M, Bitoun S, Amoura Z, Hermine O, Mariette X, Donnadieu E, Avouac J; Club for Innovative Immunotherapies in Immune-mediated Inflammatory diseases (C3I).
The Lancet Rheumatology. 2025;7(6):e434–e447.
DOI: 10.1016/S2665-9913(24)00377-1 PubMed
Published online on December 29, 2024
CAR T-Cell Therapy for Rheumatic Diseases: What Does the Future Hold?
Avouac J, Scherlinger M; Club for Innovative Immunotherapies in Immune-Mediated Inflammatory Diseases (C3I).
BioDrugs. 2025;39(1):5–19.
DOI: 10.1007/s40259-024-00692-z PubMed

Meet the experts driving the club’s work.

The C3I committees

Our actionsand publications.

Our actions

Centre mapping

Patient information

Training and webinars

Our publications

Next-generation immune cell engagers for B cell depletion in autoimmune diseases

Suspected ICANS in systemic sclerosis: think twice before corticosteroids

Immune reset after deep B-lineage depletion: remission is not reprogramming Open access

The why, what, who and when of B cell depletion in systemic lupus erythematosus: biological rationale, patient stratification and evolving therapeutic modalities Open access

Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series Open access

Roads and detours for CAR T cell therapy in autoimmune diseases

CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future? Open access

CAR T-cell therapy in autoimmune diseases: where are we and where are we going?

CAR T-Cell Therapy for Rheumatic Diseases: What Does the Future Hold?

Our actions
and publications.